Statement: Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms.
Primary_evidence: Adverse Events 1:   Total: 5/261 (1.92%)   Cholecystitis chronic 1/261 (0.38%)   Post procedural bile leak 1/261 (0.38%)   Spinal column stenosis 1/261 (0.38%)   Depression 1/261 (0.38%)   Mania 1/261 (0.38%)   Pulmonary embolism 1/261 (0.38%)
Secondary_evidence: Adverse Events 1:   Total: 12/63 (19.05%)   Febrile neutropenia *  [1]4/63 (6.35%)   Congestive heart failure *  [2]1/63 (1.59%)   Cardiac-ischemia/infarction * 1/63 (1.59%)   Vomiting *  [1]1/63 (1.59%)   Acute Pharyngitis * 1/63 (1.59%)   Infection * 3/63 (4.76%)   Neutrophil count decreased *  [1]1/63 (1.59%)   Pneumonitis/pulmonary infiltrates *  [3]1/63 (1.59%)